Franklin Biolabs is a next-generation preclinical research organization specializing in cell and gene therapy, biologics, and RNA-based therapeutics. As part of the Bioculture Group, we combine ethical sourcing, translational science, and regulatory precision to bring breakthrough treatments from lab to life.
About Franklin Biolabs
Founded in 1984 by conservationists Mary-Ann and Owen Griffiths
Company History
Headquartered in Philadelphia, Pennsylvania, Franklin Biolabs operates as the Bioculture Group’s U.S.-based research and innovation hub.
Founded under the scientific leadership of Dr. James M. Wilson, a world authority in gene therapy, Franklin Biolabs provides preclinical and translational services that enable safe, effective, and accelerated drug development.
Role within the Bioculture Group
As the research centerpiece of Bioculture’s Care to Cure model, Franklin Biolabs transforms ethically sourced NHP models and molecular platforms into actionable data that drive clinical progress.
It ensures scientific continuity across the entire value chain — from ethical breeding (Bioculture Mauritius) to regulated research (AnewCRO) and translational study execution.
U.S. Market Focus
- Preclinical and IND-enabling research.
- Gene and cell therapy vector development.
- GLP toxicology and safety studies.
- Advanced pharmacokinetics and biomarker analytics.
- Integrated bioinformatics and data analysis systems.
Core Research Services
<p>Franklin Biolabs offers a comprehensive suite of preclinical and translational research services designed for the modern era of biologics and genetic medicine.</p>
Preclinical Toxicology Studies
GLP and non-GLP safety assessments supporting IND and CTA submissions.
Pharmacokinetic (PK)
Evaluating drug absorption, metabolism, and systemic response.
Efficacy Testing
In vivo and in vitro studies to assess therapeutic performance.
Vector Development & Optimization
AAV and RNA-based vector production, characterization, and potency testing.
Biodistribution & Shedding Studies
Quantitative PCR and in situ hybridization to trace vector delivery and clearance.
Immunogenicity & Biomarker Assessment
ELISA, flow cytometry, and multiplex assays to monitor immune response.
Scientific Expertise
Franklin Biolabs is led by experienced scientists, CRO professionals, and academic collaborators who have contributed to pioneering research in genetic medicine. Their combined expertise spans molecular biology, toxicology, pharmacology, and regulatory science.
Dr. James M. Wilson, MD, PhD
Executive Chairman
Pioneer of AAV vector gene therapy.
Dr. Vatsala
Naageshwaran, PhD
20+ years in biopharmaceutical leader.
Dr. Jenny Greig
Gene therapy development and regulatory specialist.
Anthony Asfor, MBA
Expertise in CRO operations and strategic finance.
Standards & Certifications
Bioculture Mauritius operates under stringent international welfare and research standards to ensure consistency, credibility, and ethical assurance.
Industry Certifications
- AAALAC International – Accreditation for animal care and use.
- Mauritian Ministry of Agro-Industry License – Regulated breeding and export authority.
- CITES Compliance – Certified under the Convention on International Trade in Endangered Species.
Compliance Standards
- Follows USDA, CDC, and OECD welfare and research frameworks.
- Adheres to the 3Rs Principle (Replacement, Reduction, Refinement) in all operations.
Quality Assurance Protocols
- Routine audits and external welfare inspections.
- Health certification issued prior to every export.
- Full traceability via digital colony and logistics tracking systems.
Research Achievements
Franklin Biolabs scientists have contributed to several landmark advances in gene therapy and biologics development, including
Contact Bioculture (Mauritius) Ltd
For NHP supply inquiries, compliance documentation, or partnership discussions, please contact our Mauritius office directly.
- +230 217 2735
- www.bioculturegroup.com
- Pailles, Mauritius
- info@bioculturegroup.com
